Gain Therapeutics Doses First Participant in Phase 1b Clinical Trial of GT-02287 in Parkinson’s Disease
14 Mar 2025 11:45 GMT
… and Elio Ambrosio
nic.johnson@russopartnersllc.com
elio.ambrosio@russopartnersllc.com
(760) 846-9256
Virax Biolabs Presents Data on T-Cell Dysfunction in Post-acute Infection Syndromes at the 19th World Immune Regulation Meeting
13 Mar 2025 11:58 GMT
… : 303-482-6405
nic.johnson@russopartnersllc.com
View original content to download …
NervGen Engages Russo Partners LLC to Provide Public Relations Services
25 Apr 2024 23:32 GMT
… . For more information, visit www.russopartnersllc.com or follow Russo Partners on … Partners
david.schull@russopartnersllc.com
ignacio.guerrero-ros@russopartnersllc.com
858.717.2310
646 …
Gain Therapeutics Announces Oral Presentation at AD/PD 2025
06 Mar 2025 12:55 GMT
… and Elio Ambrosio
nic.johnson@russopartnersllc.com
elio.ambrosio@russopartnersllc.com
(760) 846-9256
Virax Biolabs to Present at 19th World Immune Regulation Meeting
05 Mar 2025 12:38 GMT
… : 303-482-6405
nic.johnson@russopartnersllc.com
View original content to download …
フィブロバイオロジックス (FibroBiologics)、線維芽細胞ベースの治療薬を用いたミトコンドリア活性の調節に関する新規アプローチで特許申請
05 Mar 2025 00:17 GMT
… )
ラッソ・パートナーズ
(347) 956-7697
Elizabeth.phillips@russopartnersllc.com
Catalyst Pharmaceuticals to Participate in the Barclays 27th Annual Global Healthcare Conference
04 Mar 2025 13:03 GMT
…
(858) 717-2310
david.schull@russopartnersllc.com